ADVERTISEMENT
ADVERTISEMENT
India to tackle global obesity with cheap fat-loss jabs
For India's drug giants, this marks the start of an aggressive new race.
-
AFP - Fri, 20, Mar 2026
- 16:40 EDT
- 18
.jpg)
Boxes of Ozempic and Mounjaro, semaglutide and tirzepatide injection drugs used for treating type 2 diabetes and made by Novo Nordisk and Lilly, is seen at a Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. / REUTERS/George Frey
A deluge of weight‑loss drugs is set to transform the global fight against obesity as India prepares to unleash low‑cost generic versions of injections like Ozempic after a key patent expired March 20.
The move will dramatically widen access to treatments that have long been considered a luxury, especially in middle-income countries, where soaring demand has collided with steep prices.
At clinics across Mumbai, doctors say they are already preparing for an influx in new patients.
This post is for paying subscribers only
SUBSCRIBE NOWRelated
ADVERTISEMENT
ADVERTISEMENT
E Paper
Video
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login